The VEGF Inhibitor Soluble Fms-like Tyrosine Kinase 1 Does Not Promote AKI-to-CKD Transition

(1) Background: Soluble Fms-like tyrosine kinase 1 (sFLT1) is an endogenous VEGF inhibitor. sFLT1 has been described as an anti-inflammatory treatment for diabetic nephropathy and heart fibrosis. However, sFLT1 has also been related to peritubular capillary (PTC) loss, which promotes fibrogenesis. H...

Descripción completa

Detalles Bibliográficos
Autores principales: van Aanhold, Cleo C. L., Koudijs, Angela, Dijkstra, Kyra L., Wolterbeek, Ron, Bruijn, Jan A., van Kooten, Cees, Baelde, Hans J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9456014/
https://www.ncbi.nlm.nih.gov/pubmed/36077058
http://dx.doi.org/10.3390/ijms23179660

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9456014/
https://www.ncbi.nlm.nih.gov/pubmed/36077058
http://dx.doi.org/10.3390/ijms23179660

Ejemplares similares